446284-32-8

Basic information

• Product Name: 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine
• Synonyms: 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine;1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-Methoxy-;7-Chloro-4-Methoxy-6-azaindole
• CAS NO: 446284-32-8
• Molecular Formula: C₈H₇ClN₂O
• Molecular Weight: 182.60698
• Mol File: 446284-32-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 371.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.393
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 13.30±0.40(Predicted)
• CAS DataBase Reference: 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine(446284-32-8)
• EPA Substance Registry System: 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine(446284-32-8)

Safety Data

• Hazardous Substances Data: 446284-32-8(Hazardous Substances Data)

Usage

General Description

7-Chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine is a chemical compound with the molecular formula C8H7ClN2O. It is a heterocyclic compound containing a pyrrole ring fused to a pyridine ring, and it also has a chlorine atom and a methoxy group attached to the pyrrole ring. 7-Chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine is used in the development of pharmaceutical drugs, particularly in the field of medicinal chemistry. It is also utilized in various organic synthesis processes as a reagent or intermediate. Its unique structural features make it a valuable building block for the synthesis of diverse bioactive molecules and pharmaceuticals.

Upstream product

• 917918-80-0 7-hydroxy-4-methoxy-6-azaindole 
• 124-41-4 sodium methylate 
• 425380-38-7 4-bromo-7-chloro-3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 452296-79-6 4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridine 
• 917918-80-0 C₈H₈N₂O₂ 
• 67-56-1 methanol 

Downstream Products

• 676489-50-2 2-(1-(2-(4-methoxy-7-(pyrazin-2-yl)-1H-pyrrolo[2,3-c]-pyridin-3-yl)-2-oxoethanoyl)piperidin-4-ylidene)-2-phenylethanenitrile 
• 446285-02-5 1-(4-benzoylpiperazin-1-yl)-2-(7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 1426310-90-8 1-(5-benzoylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-36-7 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-ethane-1,2-dione 
• 864953-39-9 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogen phosphate 
• 701213-73-2 (R)-1-(4-benzoyl-3-methylpiperazin-1-yl)-2-(7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 446289-32-3 N-(5-(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl)thiazol-2-yl)acetamide 
• 446289-94-7 1-(7-(2-aminothiazol-5-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(4-benzoylpiperazin-1-yl)ethane-1,2-dione 
• 619330-81-3 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 

Relevant articles and documents

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

The optimization of the 4-methoxy-6-azaindole series of HIV-1 attachment inhibitors (AIs) that originated with 1 to deliver temsavir (3, BMS-626529) is described. The most beneficial increases in potency and pharmacokinetic (PK) properties were attained by incorporating N-linked, sp2-hybridized heteroaryl rings at the 7-position of the heterocyclic nucleus. Compounds that adhered to a coplanarity model afforded targeted antiviral potency, leading to the identification of 3 with characteristics that provided for targeted exposure and PK properties in three preclinical species. However, the physical properties of 3 limited plasma exposure at higher doses, both in preclinical studies and in clinical trials as the result of dissolution- and/or solubility-limited absorption, a deficiency addressed by the preparation of the phosphonooxymethyl prodrug 4 (BMS-663068, fostemsavir). An extended-release formulation of 4 is currently in phase III clinical trials where it has shown promise as part of a drug combination therapy in highly treatment-experienced HIV-1 infected patients.

Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement

Demand remains for new inhibitors of HIV-1 replication and the inhibition of HIV-1 entry is an extremely attractive therapeutic approach. Using field-based bioisosteric replacements, we have further extended the chemotypes available for development in the HIV-1 entry inhibitor class. Moreover, using field-based disparity analysis of the compounds, 3D structure-activity relationships were derived that will be useful in the further development of these inhibitors towards clinical utility.

DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.